Skip to main content
. 2021 Nov 3;61(7):3023–3032. doi: 10.1093/rheumatology/keab826

Fig. 5.


Fig. 5

Expression levels of AC005165.1, FRZB, CRIM1 and LVRN

Expression levels of AC005165.1, FRZB, CRIM1 and LVRN upon either transfecting primary osteogenic cells with LNA GapmeRs targeting AC005165.1 (indicated with AC005165.1) or transfecting primary osteogenic cells with a negative control (cells were collected from N = 4 knee joints).